J&K&L HC: Bail is Not Absolute For Juveniles in Heinous Cases and Can be Denied to Serve Justice || Delhi HC: Expired Driving Licenses Do Not Enjoy Deemed Continuity After 2019 MV Act Amendment || MP High Court: Ex-Gratia Payments are Dependents’ Last Hope and Rules Should be Applied Liberally || Orissa HC: SC’s Mihir Rajesh Shah Directive on Written Arrest Grounds Applies Prospectively || Delhi HC: Tenant Liable For Possession Through Family; Non-Residence Claim Doesn’t Excuse Liability || Allahabad High Court: Muslims Can Use Guardians and Wards Act Provisions to Seek Minor’s Custody || Delhi High Court: Earlier Buyer Can Seek Cancellation of a Later Sale; Prior Rights Prevail || Madras HC: 'Geetham' Restaurants Did Not Infringe 'Sangeetha' Trademark But Liable For Passing Off || Bombay High Court: Disabled Employee Shifted Cadre Can’t Claim Past Service Seniority || Supreme Court: Person Accepting a Section 28A Award May Seek Enhancement Via Appeals

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :